Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignanciesStefan Faderl, Michael J. Keating, Hagop M. Kantarjian et al.|Blood|2003Cited by 254
Non-Hodgkin’s Lymphomas, Version 1.2013Andrew D. Zelenetz, Maoko Naganuma, William G. Wierda et al.|Journal of the National Comprehensive Cancer Network|2013Cited by 76